PRECISE 第2版:前列腺癌主动监测患者前列腺磁共振成像报告更新建议
国际共识组采用RAND/UCLA适当性方法更新PRECISE建议,38名专家对193条陈述评分。更新明确MRI最低图像质量标准、与基线和前次扫描对比、PRECISE评分取任一病灶最大值、PRECISE 3细分为可见与非可见病变、PI-RADS/Likert≥3病灶在T2加权成像测量并尽量图示化、PRECISE 5为进展至≥T3a期;肿瘤大小测量方法未达成共识,确定显著增大需更多研究。
要点
- MRI须达最低图像质量标准,否则评为X分;当前扫描应与基线和前次扫描对比。
- PRECISE评分取任一病灶最大值;PRECISE 3细分为3-V可见与3-NonV不可见病变。
- PI-RADS/Likert≥3病灶在T2加权成像测量并尽量图示化;PRECISE 5为进展至≥T3a期。
核心结论
- 更新后的PRECISE建议反映了专家共识意见,涉及主动监测中前列腺MRI的最低标准和报告标准。
研究设计与样本
- 由38名专家组成的小组采用正式的RAND/UCLA适当性方法共识方法学。
主要发现
- 参与者同意MRI扫描必须满足最低图像质量标准(中位数9分),否则因质量不足评为X分。
- 当前扫描应与基线和前次扫描对比(中位数9分),PRECISE评分取任一病灶的最大值(中位数8分)。
- PRECISE 3(MRI稳定)细分为3-V(可见)和3-NonV(不可见)病变(中位数9分)。
- PI-RADS/Likert≥3病灶应在T2加权成像上测量,使用其他序列辅助识别(中位数8分),并尽可能以图示(示意图、截图或轮廓)报告(中位数9分)。
- 关于如何测量肿瘤大小未达成共识;确定显著大小增加需要更多研究(中位数9分)。
关键数值与推荐
- MRI扫描须满足最低图像质量标准(中位数9分),否则评为X分。
- 当前扫描应与基线和前次扫描对比(中位数9分),PRECISE评分取任一病灶最大值(中位数8分)。
- PRECISE 3细分为3-V(可见)和3-NonV(不可见)病变(中位数9分)。
- PI-RADS/Likert≥3病灶在T2加权成像测量(中位数8分),尽可能图示化报告(中位数9分)。
- PRECISE 5为进展至≥T3a期(中位数9分)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 关于如何测量肿瘤大小未达成共识。
- 确定显著大小增加需要更多研究(中位数9分)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations standardise the reporting of prostate magnetic resonance imaging (MRI) in patients on active surveillance (AS) for prostate cancer. An international consensus group recently updated these recommendations and identified the areas of uncertainty. METHODS: A panel of 38 experts used the formal RAND/UCLA Appropriateness Method consensus methodology. Panellists scored 193 statements using a 1-9 agreement scale, where 9 means full agreement. A summary of agreement, uncertainty, or disagreement (derived from the group median score) and consensus (determined using the Interpercentile Range Adjusted for Symmetry method) was calculated for each statement and presented for discussion before individual rescoring. KEY FINDINGS AND LIMITATIONS: Participants agreed that MRI scans must meet a minimum image quality standard (median 9) or be given a score of 'X' for insufficient quality. The current scan should be compared with both baseline and previous scans (median 9), with the PRECISE score being the maximum from any lesion (median 8). PRECISE 3 (stable MRI) was subdivided into 3-V (visible) and 3-NonV (nonvisible) disease (median 9). Prostate Imaging Reporting and Data System/Likert ≥3 lesions should be measured on T2-weighted imaging, using other sequences to aid in the identification (median 8), and whenever possible, reported pictorially (diagrams, screenshots, or contours; median 9). There was no consensus on how to measure tumour size. More research is needed to determine a significant size increase (median 9). PRECISE 5 was clarified as progression to stage ≥T3a (median 9). CONCLUSIONS AND CLINICAL IMPLICATIONS: The updated PRECISE recommendations reflect expert consensus opinion on minimal standards and reporting criteria for prostate MRI in AS.
引用
- Englman C, Maffei D, Allen C, et al. PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. Eur Urol. 2024. PMID: 38556436. doi:10.1016/j.eururo.2024.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。